A custom-fit degradable implant for filling bone defects after craniofacial surgery; a study shows Bard's LifeStent as superior to stentless angioplasty; Micrus' DeltaPAQ and DeltaPlush microcoils cleared in Japan; and CorMatrix's cardiac tissue repair wins CE Mark.
Resobone custom-fit degradable implants for bone defects: Researchers at the Fraunhofer Institute for Laser Technology ILT in Aachen, Germany, have developed a custom-fit degradable implant for filling bone defects after craniofacial surgery. Currently defects are filled with filling material or previously removed bone. The new method uses a CT image template and a technique called selective laser melting to create a perfectly fitting implant consisting of a porous material into which adjacent bone can grow. The materials used, synthetic polylactide and tricalcium phosphate, are resorbed as the bone grows, giving rise to the name "Resobone." The entire process, from obtaining imaging of the patient's anatomy to having an implant ready can be done in just a few hours. The technique can be used to close defects of up to 25 square centimeters in size.
Study: Bard's LifeStent superior to stentless angioplasty: C.R. Bard Inc. (NYSE:BCR) announced the publication of data from its Resilient study in Circulation: Cardiovascular Interventions. The results show that Bard's LifeStent vascular stent, currently the only stent approved by the Food & Drug Administration for use in the femoral and proximal popliteal arteries, can prevent narrowing of these arteries when used during percutaneous transluminal angioplasty (PTA).